These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders. Borrows R; Scheer A; Cockwell P; Braun F; Anagnostopoulos I; Riess H; Zimmermann H; Trappe RU Ann Hematol; 2019 Mar; 98(3):625-632. PubMed ID: 30680506 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Quinlan SC; Pfeiffer RM; Morton LM; Engels EA Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909 [TBL] [Abstract][Full Text] [Related]
14. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients. Liu M; Husain S; Famure O; Li Y; Kim SJ Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885 [TBL] [Abstract][Full Text] [Related]
15. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859 [TBL] [Abstract][Full Text] [Related]
16. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621 [TBL] [Abstract][Full Text] [Related]
17. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308 [TBL] [Abstract][Full Text] [Related]
18. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165 [TBL] [Abstract][Full Text] [Related]
19. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
20. p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression. Proust A; Rincé P; Creidy R; Lazure T; Joab I; Garçon L; Fabre M; Guettier C; Raphael M Am J Pathol; 2011 Oct; 179(4):1630-7. PubMed ID: 21871426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]